Baseline characteristics of the patients
Among the 3,562 patients who encountered dialysis-requiring AKI and suspected infection during the study period, 1,764 were excluded due to either having a quick SOFA score of less than 2 or not having available assessment data on organ dysfunction. Of the remaining 1,798 patients, 1,397 who had an acute increase in SOFA score of 2 or higher were enrolled in the study (Fig. 1). Their mean age was 63.81 ± 16.38 years; 973 (69.65%) patients were male; 578 (41.37%) patients had diabetes; and 748 (53.54%) patients had hypertension. The leading sources of sepsis were respiratory tract infections (59.99%), followed by device- or catheter-associated (26.06%), and blood stream infections (20.47%). (Table 1A)
Table 1 Patients characteristics across the three clusters which were revealed by 22 parameters
(A) Demographic characteristics at baseline
Variable
|
Overall
(n=1,397)
|
Cluster 1
(n=360)
|
Cluster 2
(n=594)
|
Cluster 3
(n=443)
|
p value*
|
Age, years
|
63.81 ± 16.38
|
65.62 ± 15.88
|
67.98 ± 15.72
|
56.76 ± 15.34
|
<0.001
|
Male sex
|
973 (69.65%)
|
254 (70.56%)
|
408 (68.69%)
|
311 (70.2%)
|
0.79
|
Current smoker or ex-smoker
|
214 (15.32%)
|
57 (15.83%)
|
74 (12.46%)
|
83 (18.74%)
|
0.02
|
Diabetes mellitus
|
578 (41.37%)
|
176 (48.89%)
|
257 (43.27%)
|
145 (32.73%)
|
<0.001
|
Hypertension
|
748 (53.54%)
|
210 (58.33%)
|
340 (57.24%)
|
198 (44.7%)
|
<0.001
|
Coronary artery disease
|
418 (29.92%)
|
109 (30.28%)
|
192 (32.32%)
|
117 (26.41%)
|
0.12
|
Stroke
|
111 (7.95%)
|
33 (9.17%)
|
63 (10.61%)
|
15 (3.39%)
|
<0.001
|
Peripheral arterial occlusive disease
|
56 (4.01%)
|
26 (7.22%)
|
26 (4.38%)
|
4 (0.9%)
|
<0.001
|
Advanced heart failure, NYHA Fc III or IV
|
269 (19.26%)
|
81 (22.50%)
|
97 (16.33%)
|
91 (20.54%)
|
0.046
|
Chronic obstructive pulmonary disease
|
72 (5.15%)
|
18 (5%)
|
42 (7.07%)
|
12 (2.71%)
|
0.007
|
Liver cirrhosis
|
177 (12.67%)
|
38 (10.56%)
|
85 (14.31%)
|
54 (12.19%)
|
0.22
|
Cancer
|
295 (21.12%)
|
89 (24.72%)
|
137 (23.06%)
|
69 (15.58%)
|
0.002
|
Charlson Comorbidity Index
|
5.15 ± 2.24
|
5.47 ± 2.19
|
5.72 ± 2.24
|
4.14 ± 1.9
|
<0.001
|
Baseline eGFR, ml/min/1.73m2
|
60.5 ± 32.49
|
49.47 ± 33.26
|
57.13 ± 29.27
|
73.97 ± 31.47
|
<0.001
|
Body mass index, kg/m2
|
24.49 ± 4.8
|
24.26 ± 4.89
|
23.92 ± 4.37
|
25.44 ± 5.13
|
<0.001
|
Index admission year before 2013
|
735 (52.61%)
|
170 (47.22%)
|
334 (56.23%)
|
231 (52.14%)
|
0.03
|
Surgery
|
796 (56.98%)
|
186 (51.67%)
|
346 (58.25%)
|
264 (59.59%)
|
0.06
|
Total parenteral nutrition
|
328 (23.48%)
|
86 (23.89%)
|
156 (26.26%)
|
86 (19.41%)
|
0.04
|
Mechanical ventilation
|
1,156 (82.75%)
|
203 (56.39%)
|
534 (89.9%)
|
419 (94.58%)
|
<0.001
|
Cardiopulmonary resuscitation
|
289 (20.69%)
|
56 (15.56%)
|
110 (18.52%)
|
123 (27.77%)
|
<0.001
|
ECMO
|
474 (33.93%)
|
74 (20.56%)
|
154 (25.93%)
|
246 (55.53%)
|
<0.001
|
Source of sepsis
|
|
|
|
|
|
Respiratory tract
|
838 (59.99%)
|
204 (56.67%)
|
368 (61.95%)
|
266 (60.05%)
|
0.27
|
Intra-abdominal
|
107 (7.66%)
|
32 (8.89%)
|
59 (9.93%)
|
16 (3.61%)
|
0.001
|
Skin or soft-tissue
|
120 (8.59%)
|
28 (7.78%)
|
56 (9.43%)
|
36 (8.13%)
|
0.62
|
Genitourinary tract
|
118 (8.45%)
|
28 (7.78%)
|
45 (7.58%)
|
45 (10.16%)
|
0.29
|
Device or catheter associated
|
364 (26.06%)
|
79 (21.94%)
|
169 (28.45%)
|
116 (26.19%)
|
0.09
|
Blood stream
|
286 (20.47%)
|
69 (19.17%)
|
129 (21.72%)
|
88 (19.86%)
|
0.59
|
Others / Unknown
|
406 (29.06%)
|
121 (33.61%)
|
151 (25.42%)
|
134 (30.25%)
|
0.02
|
Indication for dialysis initiation
|
|
|
|
|
|
Azotaemia with symptoms
|
734 (52.54%)
|
222 (61.67%)
|
364 (61.28%)
|
148 (33.41%)
|
<0.001
|
Fluid overload
|
623 (44.6%)
|
159 (44.17%)
|
246 (41.41%)
|
218 (49.21%)
|
0.04
|
Electrolyte imbalance
|
155 (11.1%)
|
37 (10.28%)
|
56 (9.43%)
|
62 (14%)
|
0.06
|
Metabolic acidosis
|
278 (19.9%)
|
50 (13.89%)
|
97 (16.33%)
|
131 (29.57%)
|
<0.001
|
Oliguria
|
941 (67.36%)
|
219 (60.83%)
|
387 (65.15%)
|
335 (75.62%)
|
<0.001
|
Others
|
102 (7.3%)
|
18 (5%)
|
34 (5.72%)
|
50 (11.29%)
|
0.001
|
Modality at the first RRT
|
|
|
|
|
<0.001
|
CRRT
|
832 (59.56%)
|
143 (39.72%)
|
320 (53.87%)
|
369 (83.3%)
|
|
SLED
|
274 (19.61%)
|
90 (25%)
|
134 (22.56%)
|
50 (11.29%)
|
|
iHD
|
291 (20.83%)
|
127 (35.28%)
|
140 (23.57%)
|
24 (5.42%)
|
|
(B) Baseline clinical data upon initialising RRT
Variable
|
Overall
(n=1,397)
|
Cluster 1
(n=360)
|
Cluster 2
(n=594)
|
Cluster 3
(n=443)
|
p value*
|
Urine volume, mL/day (median [IQR])
|
320 (90-768)
|
420 (140-626.7)
|
350 (120-833.8)
|
200 (50-607.5)
|
0.005
|
Glasgow Coma Scale
|
8.24 ± 4.04
|
13.46 ± 2.07
|
7.69 ± 2.21
|
4.75 ± 2.57
|
<0.001
|
Body temperature, degree Celsius
|
36.58 ± 1.15
|
36.50 ± 1.02
|
36.65 ± 1.08
|
36.55 ± 1.33
|
0.13
|
Heart rate, beats per minute
|
101.65 ± 20.84
|
100.59 ± 21.66
|
97.94 ± 18.73
|
107.5 ± 21.58
|
<0.001
|
Mean arterial pressure, mmHg
|
78.62 ± 16.33
|
82.57 ± 16.1
|
80.22 ± 14.93
|
73.27 ± 16.97
|
<0.001
|
Ratio of PaO2 to fraction of inspired oxygen (median [IQR])
|
219 (130-356.6)
|
236.4 (147.9-370.4)
|
271 (176.2-395.5)
|
137.7 (88.5-242.2)
|
<0.001
|
Blood urea nitrogen, mg/dL
|
74.05 ± 44.06
|
87.54 ± 43.31
|
80.62 ± 44.08
|
54.26 ± 37.44
|
<0.001
|
Serum creatinine, mg/dL
|
3.75 ± 2.27
|
4.86 ± 2.52
|
3.79 ± 2.2
|
2.8 ± 1.65
|
<0.001
|
Sodium, mmol/L
|
139.99 ± 8.42
|
136.78 ± 7.5
|
139.87 ± 8.03
|
142.42 ± 8.79
|
<0.001
|
Potassium, mmol/L
|
4.31 ± 0.88
|
4.43 ± 0.85
|
4.25 ± 0.85
|
4.29 ± 0.95
|
0.008
|
White blood cells, 103cells/μL
|
13.73 ± 7.91
|
13.9 ± 8.26
|
13.74 ± 7.74
|
13.6 ± 7.86
|
0.86
|
Hemoglobin, g/dL
|
10.2 ± 2.2
|
9.84 ± 1.98
|
9.86 ± 1.78
|
10.96 ± 2.64
|
<0.001
|
Platelets, 103cells/μL
|
126.06 ± 87.95
|
160.18 ± 96.82
|
115. 79 ± 80.12
|
112.1 ± 83.71
|
<0.001
|
Total bilirubin, mg/dL
|
4.48 ± 7.42
|
3.15 ± 5.8
|
5.25 ± 8.58
|
4.52 ± 6.74
|
<0.001
|
Bicarbonate, mmol/L
|
19.5 ± 5.32
|
19.47 ± 5.31
|
19.53 ± 5.23
|
19.49 ± 5.45
|
0.98
|
Lactate, mmol/L
|
5.22 ± 5.38
|
3.09 ± 3.52
|
4.37 ± 4.53
|
8.10 ± 6.39
|
<0.001
|
Inotropic equivalent, μg/kg/min (median [IQR])
|
7.80 (0-19.70)
|
1.57 (0-9.59)
|
6.4 (0-16.5)
|
16.2 (7.4-31.9)
|
<0.001
|
APACH II score (median [IQR])
|
20 (16-24)
|
15 (11-19)
|
19 (17-22.8)
|
25 (21-28)
|
<0.001
|
SOFA score (median [IQR])
|
13 (11-16)
|
10 (8-11)
|
13 (11-15)
|
16 (14-18)
|
<0.001
|
Data are presented as mean (standard deviation), unless otherwise specified. *Variables are compared across the clusters by the one way analysis of variance, Kruskal-Wallis test, and χ2 test as indicated.
Abbreviations: NYHA Fc, New York Heart Association functional class; eGFR, estimated glomerular filtration rate; ECMO, extracorporeal membrane oxygenation; RRT, renal replacement therapy; CRRT, continuous renal replacement therapy; SLED, sustained low efficiency dialysis; iHD, intermittent haemodialysis; RRT, renal replacement therapy; IQR, interquartile range; APACH, Acute Physiology and Chronic Health Evaluation; SOFA, sequential organ failure assessment.
Table 1B shows the clinical data upon initialising RRT. The median IE was 7.8 (interquartile range [IQR] 0-19.7), median SOFA score was 13 (IQR 11–16), and the median Acute Physiology and Chronic Health Evaluation (APACH) II score was 20 (IQR 16–24). The most frequent indication for dialysis initiation was oliguria (67.41%), followed by symptomatic azotaemia (52.54%) and fluid overload (44.60%). The modality of first dialysis was CRRT in 59.56%, SLED in 19.61% and iHD in 20.83% of the patients.
Clustering of patients with SA-AKI
Consensus cluster analysis was performed to agnostically identify distinct subpopulations of patients. The heat maps of consensus matrix and cluster-consensus plots by different cluster sizes are shown in Additional file 1: Fig. S1A–E. Clustering with k of more than 3 generated one or two clusters with a mean consensus value of less than 0.7, indicating less stability of the cluster membership (Additional file 1: Fig. S1F). The changes in the area under the CDF curve did not conspicuously increase when the cluster size k was more than 3 (Additional file 1: Fig. S2). Accordingly, we identified three clusters that fairly represented the clinical parameters upon initialising RRT. Cluster 1 comprised 360 (25.77%) patients, and cluster 2 consisted of 594 (42.52%) patients, whereas cluster 3 had 443 (31.71%) patients. The mean consensus value was 0.78 for cluster 1, 0.72 for cluster 2 and 0.86 for cluster 3.
The distribution of most baseline characteristics was significantly different across the three clusters, except for sex, history of coronary artery disease, liver cirrhosis, receiving surgery, body temperature, white blood cells count and serum bicarbonate level (Table 1 and Additional file 1: Fig. S3 and S4). Fig. 2A shows the standardised difference in the baseline characteristics according to each cluster. Key features of the clusters were depicted by having an absolute standardised difference of ≥ 0.3. Cluster 1 included individuals with poor baseline renal functional reserves, as indicated by their higher blood urea nitrogen and serum creatinine and lower baseline eGFR. However, the severity of acute illness seems to be lower, suggested by their higher Glasgow Coma Scale (GCS) and lower serum lactate, IE and APACH II and SOFA scores upon initialising RRT. In contrast, cluster 3 comprised individuals with favourable baseline conditions, that is, younger age, higher baseline eGFR and lower CCI. Nevertheless, acute clinical status upon initialising RRT was worst in cluster 3, as observed by their lower GCS, mean arterial pressure (MAP) and PaO2 to fraction of inspired oxygen ratio and higher serum lactate, IE, APACH II and SOFA scores. Patients in cluster 3 were more likely to receive mechanical ventilation, extracorporeal membrane oxygenation and CRRT as their first dialysis.
Association between sub-phenotypes and clinical outcomes
All enrolled patients were followed up for a median of 31 days (IQR, 8–123 days). All-cause mortality occurred in 901 (65.12%) patients. Moreover, 139 (9.51%) survivors were dialysis dependent, whereas 357 (25.38%) survivors were free of dialysis. Ninety days after hospital discharge, patients in cluster 3 had the highest mortality rate (78.1% vs. 67% [cluster 2] vs. 43.61% [cluster 1]; p < 0.001). Kaplan–Meier curves showed that survival differences across the three clusters were highly significant (log rank p < 0.001)(Fig. 2B). After adjusting for age, sex, baseline eGFR and CCI, Cox hazard analysis showed that patients in clusters 2 (adjusted hazard ratio [HR], 1.8; 95% CI, 1.49–2.16) and 3 (adjusted HR, 3.06; 95% CI, 2.5–3.74) were associated with an increased risk of death compared with those in cluster 1.
The possibility of being free of dialysis 90 days after hospital discharge was highest in cluster 1 (33.89% vs. 24.58% [cluster 2] vs. 20.09% [cluster 3]; p < 0.001). The CIF plot demonstrated that the phenotypic cluster was associated with different probabilities of being free of dialysis (Gray’s test p < 0.001)(Fig. 2C). After adjusting for age, sex, baseline eGFR and CCI in the Fine–Gray sub-distribution hazard model, patients in clusters 2 (adjusted sub-distribution hazard ratio [sHR], 0.69; 95% CI, 0.54–0.87) and 3 (adjusted sHR, 0.4; 95% CI, 0.3–0.52) were less likely to become free of dialysis than those in cluster 1.
We performed another supplementary clustering using the K-nearest neighbour graph structure and Louvain algorithm [19, 36]. This approach identified two clusters and revealed a similar observation: a cluster featured by older age, more comorbidity and lower baseline eGFR, but with less severity of acute illness, was associated with better survival; meanwhile, another cluster featured by younger age, fewer comorbidities, higher baseline eGFR but with higher severity of acute illness was associated with an increased risk of death (Additional file 1: Fig. S5).
Hyperlactatemia as a key feature of the unfavourable sub-phenotype
Through the cluster analysis, we identified a sub-phenotype (cluster 3) of patients with a higher mortality risk and lower probability of being free of dialysis. Cluster 3 had a notably higher serum lactate level upon initialising RRT (Fig. 2A and Additional file 1: Fig. S4P). However, cluster 1, which had favourable clinical outcomes, was characterised by lower serum lactate level. This association was also evident in the supplementary clustering analyses (Additional file 1: Fig. S5).
Therefore, we examined the association of serum lactate level with clinical outcomes in this study. By applying the GAM with adjustment for age, sex, baseline eGFR, CCI and MAP upon initialising RRT, the estimated probability of mortality augmented when the serum lactate level was equal to or more than 3.1 mmol/L (Fig. 3). Baseline clinical variables were significantly different in many aspects between patients with serum lactate level of less than 3.1 mmol/L and those with serum lactate levels of ≥ 3.1 mmol/L upon initialising RRT (Additional file 1: Table S1).
Pre-dialysis hyperlactatemia predicts death and dialysis dependence
Whether serum lactate levels are independently associated with mortality or kidney recovery after AKI remains controversial [10, 25, 28, 37, 38]. Thus, we applied a multivariable Cox proportional hazards model and included all variables listed in Table 1 to identify factors associated with mortality after dialysis-requiring SA-AKI. Serum lactate levels of ≥ 3.1 mmol/L upon initialising RRT independently predict all-cause mortality (adjusted HR, 1.23; 95% CI, 1.05–1.44)(Table 2). The Kaplan–Meier plot revealed that patients with hyperlactatemia of ≥ 3.1 mmol/L upon initialising RRT had poor survival (log rank p < 0.001)(Fig. 4A). After controlling for mortality as a competing risk and adjusting for all variables listed in Table 1, patients who had hyperlactatemia of ≥ 3.1 mmol/L upon initialising RRT were less likely to become free of dialysis (adjusted sHR, 0.74; 95% CI, 0.57–0.97)(Table 2). Moreover, the CIF plot depicted that serum lactate levels of less than 3.1 mmol/L upon initialising RRT were associated with a higher probability of being free of dialysis after dialysis-requiring SA-AKI (Gray’s test p < 0.001)(Fig. 4B).
Table 2
Multivariable-adjusted analysis for independent predictors for clinical outcomes.
Variables
|
Mortality*
|
Being free of dialysis†
|
HR*, ‡ (95% CI)
|
P
|
sHR†, ‡ (95% CI)
|
P
|
Age, years
|
1.02 (1.01-1.02)
|
<0.001
|
|
ns
|
Chronic obstructive pulmonary disease
|
|
ns
|
1.84 (1.09-3.09)
|
0.02
|
Cancer
|
1.46 (1.19-1.79)
|
<0.001
|
0.69 (0.49-0.96)
|
0.03
|
Index admission year before 2013
|
2.03 (1.69-2.43)
|
<0.001
|
0.56 (0.42-0.74)
|
<0.001
|
Baseline eGFR, ml/min/1.73m2
|
|
ns
|
1.006 (1.002-1.01)
|
0.004
|
Surgery
|
0.76 (0.65-0.89)
|
<0.001
|
1.37 (1.07-1.74)
|
0.01
|
Dialysis initiation due to symptomatic azotaemia
|
0.8 (0.68-0.94)
|
0.008
|
|
ns
|
log(urine volume, mL/day)
|
|
ns
|
1.12 (1.04-1.22)
|
0.004
|
Glasgow Coma Scale
|
0.95 (0.92-0.98)
|
0.001
|
1.05 (1.001-1.11)
|
0.046
|
Body temperature, degree Celsius
|
0.92 (0.87-0.98)
|
0.01
|
|
ns
|
Mean arterial pressure, mmHg
|
0.99 (0.99-0.99)
|
<0.001
|
1.01 (1.003-1.02)
|
0.005
|
Blood urea nitrogen, mg/dL
|
1.004 (1.002-1.006)
|
<0.001
|
|
ns
|
Serum creatinine, mg/dL
|
0.89 (0.85-0.94)
|
<0.001
|
|
ns
|
Sodium, mmol/L
|
1.01 (1.003-1.02)
|
0.01
|
|
ns
|
Hemoglobin, g/dL
|
|
ns
|
1.07 (1.007-1.13)
|
0.03
|
Platelets, 103cells/µL
|
0.999 (0.998-1)
|
0.02
|
1.002 (1-1.003)
|
0.02
|
Total bilirubin, mg/dL
|
1.02 (1.01-1.031)
|
<0.001
|
0.96 (0.94-0.99)
|
0.002
|
Bicarbonate, mmol/L
|
|
ns
|
0.97 (0.94-0.995)
|
0.03
|
Lactate ≥ 3.1 mmol/L
|
1.23 (1.05-1.44)
|
0.01
|
0.74 (0.57-0.97)
|
0.03
|
SOFA score
|
1.06 (1.02-1.1)
|
0.004
|
|
ns
|
*Multivariable Cox regression analysis of hazard ratios (HR) for mortality. |
†Multivariable Fine-Gray model was used, higher sub-distribution hazard ratio (sHR) implies higher probability of kidney recovery from dialysis, taking mortality as a competing risk. |
‡Other factors included within both models which are not statistically significant: sex, smoking, diabetes, hypertension, coronary artery disease, stroke, peripheral arterial occlusive disease, advanced heart failure, liver cirrhosis, Charlson Comorbidity Index, body mass index, total parenteral nutrition, mechanical ventilation, cardiopulmonary resuscitation, extracorporeal membrane oxygenation, origin of sepsis, indications of dialysis initiations other than symptomatic azotaemia, modality at the first RRT, heart rate, ratio of PaO2 to fraction of inspired oxygen, potassium, white blood cells count, inotropic equivalent, and APACH II score. |
Abbreviations: CI: confidence interval; ns: not significant; eGFR, estimated glomerular filtration rate. |
External validation
To validate the predictive role of hyperlactatemia, we analysed a multi-centre database of the nationwide epidemiology and prognosis of dialysis-requiring AKI (NEP-AKI-D) study [6, 8]. We extracted a subset of 190 patients with dialysis-requiring SA-AKI who underwent surgery in the index admission between 2014 and 2016 (Additional file 1: Supplementary Methods, Fig. S6 and Table S2). Considering our main findings, the Kaplan–Meier curves showed that patients with hyperlactatemia of ≥ 3.1 mmol/L upon initialising RRT was associated with lower survival than those with serum lactate levels of less than 3.1 mmol/L (log rank p = 0.002)(Fig. 5). After adjusting for age, sex, baseline eGFR, CCI and MAP and SOFA scores upon initialising RRT, Cox hazard analysis showed that patients who had pre-dialysis hyperlactatemia of ≥ 3.1 mmol/L had increased risks of death (adjusted HR, 1.6; 95% CI, 1.1–2.33)(Additional file 1: Fig. S7).